Oppenheimer Asset Management Inc. trimmed its holdings in Sanofi (NYSE:SNY) by 6.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 157,602 shares of the company’s stock after selling 10,787 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Sanofi were worth $7,551,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC acquired a new position in shares of Sanofi in the 1st quarter valued at about $113,000. Parallel Advisors LLC lifted its stake in shares of Sanofi by 42.5% in the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Sanofi by 142.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in shares of Sanofi by 6,188.3% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after purchasing an additional 3,713 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its stake in shares of Sanofi by 95.8% in the 1st quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock valued at $210,000 after purchasing an additional 2,087 shares in the last quarter. 9.33% of the stock is currently owned by institutional investors and hedge funds.
In other news, major shareholder Sanofi acquired 60,595 shares of Sanofi stock in a transaction dated Wednesday, August 23rd. The stock was bought at an average price of $478.98 per share, for a total transaction of $29,023,793.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.00% of the company’s stock.
Several research firms have recently weighed in on SNY. BidaskClub lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Argus raised their target price on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Friday, June 2nd. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a report on Friday. Finally, HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $54.00.
Shares of Sanofi (NYSE:SNY) opened at 48.43 on Friday. Sanofi has a one year low of $36.81 and a one year high of $50.24. The company has a market capitalization of $121.63 billion, a P/E ratio of 11.54 and a beta of 0.88. The stock has a 50 day moving average price of $48.30 and a 200-day moving average price of $47.32.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. The company’s quarterly revenue was down 2.3% on a year-over-year basis. Equities research analysts predict that Sanofi will post $3.34 earnings per share for the current fiscal year.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.